LiuBXSunWKongXQ. Perirenal fat: a unique fat pad and potential target for cardiovascular disease. Angiology. 2019;70(7):584–93.
2.
KatsikiNPerez-MartinezPAnagnostisPMikhailidisDPKaragiannisA. Is nonalcoholic fatty liver disease indeed the hepatic manifestation of metabolic syndrome?Curr Vasc Pharmacol. 2018;16(3):219–27.
3.
KatsikiNMikhailidisDPMantzorosCS. Non-alcoholic fatty liver disease and dyslipidemia: an update. Metabolism. 2016;65(8):1109–23.
4.
KatsikiNPurrelloFTsioufisCMikhailidisDP. Cardiovascular disease prevention strategies for type 2 diabetes mellitus. Expert Opin Pharmacother. 2017;18(12):1243–60.
5.
LiLLiuDWYanHYWangZYZhaoSHWangB. Obesity is an independent risk factor for non-alcoholic fatty liver disease: evidence from a meta-analysis of 21 cohort studies. Obes Rev. 2016;17(6):510–9.
6.
WuSWuFDingYHouJBiJZhangZ. Association of non-alcoholic fatty liver disease with major adverse cardiovascular events: a systematic review and meta-analysis. Sci Rep. 2016;6:33386.
7.
WijarnpreechaKPanjawatananPLekuthaiNThongprayoonCCheungpasitpornWUngprasertP. Hyperuricaemia and risk of nonalcoholic fatty liver disease: a meta-analysis. Liver Int. 2017;37(6):906–18.
8.
Friedrich-RustMSchoelzelFMaierS. Severity of coronary artery disease is associated with non-alcoholic fatty liver disease: a single-blinded prospective mono-center study. PLoS One. 2017;12(10):e0186720.
9.
ZebILiDBudoffMJ. Nonalcoholic fatty liver disease and incident cardiac events: the multi-ethnic study of atherosclerosis. J Am Coll Cardiol. 2016;67(16):1965–6.
10.
MullishBHForlanoRManousouPMikhailidisDP. Non-alcoholic fatty liver disease and cardiovascular risk: an update. Expert Rev Gastroenterol Hepatol. 2018;12(12):1175–7.
11.
AthyrosVGTziomalosKKatsikiNDoumasMKaragiannisAMikhailidisDP. Cardiovascular risk across the histological spectrum and the clinical manifestations of non-alcoholic fatty liver disease: an update. World J Gastroenterol. 2015;21(22):6820–34.
12.
OniETAgatstonASBlahaMJ. A systematic review: burden and severity of subclinical cardiovascular disease among those with nonalcoholic fatty liver; should we care?Atherosclerosis. 2013;230(2):258–67.
13.
KawasakiSHasegawaOSatohSNumataKTerauchiY. Sonographic assessment of fatty liver infiltration using the measurement of para- and perirenal fat thickness. J Clin Ultrasound. 2010;38(9):470–4.
14.
KatsikiNMikhailidisDPWierzbickiAS. Epicardial fat and vascular risk: a narrative review. Curr Opin Cardiol. 2013;28(4):458–63.
15.
IacobellisG. Local and systemic effects of the multifaceted epicardial adipose tissue depot. Nat Rev Endocrinol. 2015;11(6):363–71.
16.
WhayneTFJr. Epicardial fat thickness in heart failure and other clinical conditions. Angiology. 2013;64(3):169–72.
17.
PatelVBShahSVermaSOuditGY. Epicardial adipose tissue as a metabolic transducer: role in heart failure and coronary artery disease. Heart Fail Rev. 2017;22(6):889–902.
18.
KatsikiNDoumasMMikhailidisDP. Lipids, statins and heart failure: an update. Curr Pharm Des. 2016;22(31):4796–806.
19.
GaetaMBanderaFTassinariF. Is epicardial fat depot associated with atrial fibrillation? A systematic review and meta-analysis. Europace. 2017;19(5):747–52.
20.
FullerBGarlandJAnneSBehRMcNevinDTseR. Increased epicardial fat thickness in sudden death from stable coronary artery atherosclerosis. Am J Forensic Med Pathol. 2017;38(2):162–6.
21.
PabonMAManochaKCheungJWLoJC. Linking arrhythmias and adipocytes: insights, mechanisms, and future directions. Front Physiol. 2018;9:1752.
22.
HjelmgaardKEschenRBSchmidtEBAndreasenJJLundbye-ChristensenS. Fatty acid composition in various types of cardiac adipose tissues and its relation to the fatty acid content of atrial tissue. Nutrients. 2018;10(10):pii: E1506.
23.
MannoCCampobassoNNardecchiaA. Relationship of para- and perirenal fat and epicardial fat with metabolic parameters in overweight and obese subjects. Eat Weight Disord. 2019;24(1):67–72.
24.
ChauYYBandieraRSerrelsA. Visceral and subcutaneous fat have different origins and evidence supports a mesothelial source. Nat Cell Biol. 2014;16(4):367–75.
25.
AlempijevicTDragasevicSZecSPopovicDMilosavljevicT. Non-alcoholic fatty pancreas disease. Postgrad Med J. 2017;93(1098):226–30.
KimMKChunHJParkJH. The association between ectopic fat in the pancreas and subclinical atherosclerosis in type 2 diabetes. Diabetes Res Clin Pract. 2014;106(3):590–6.
28.
OzturkKDoganTCelikkanatS. The association of fatty pancreas with subclinical atherosclerosis in nonalcoholic fatty liver disease. Eur J Gastroenterol Hepatol. 2018;30(4):411–7.
29.
LimS. Ectopic fat assessment focusing on cardiometabolic and renal risk. Endocrinol Metab (Seoul). 2014;29(1):1–4.
30.
RandrianarisoaEStefanNFritscheA. Periaortic adipose tissue compared with peribrachial adipose tissue mass as markers and possible modulators of cardiometabolic risk. Angiology. 2018;69(10):854–60.
31.
ChatterjeeTKStollLLDenningGM. Proinflammatory phenotype of perivascular adipocytes: influence of high-fat feeding. Circ Res. 2009;104(4):541–9.
32.
Błachnio-ZabielskaAGrycelSChacińskaMZabielskiP. The role of adipose tissue and excess of fatty acids in the induction of insulin resistance in skeletal muscle. Postepy Hig Med Dosw (Online). 2016;70(0):1142–9.
33.
TherkelsenKEPedleyASpeliotesEK. Intramuscular fat and associations with metabolic risk factors in the Framingham Heart Study. Arterioscler Thromb Vasc Biol. 2013;33(4):863–70.
34.
VivodtzevIMoncharmontLTamisierR. Quadriceps muscle fat infiltration is associated with cardiometabolic risk in COPD. Clin Physiol Funct Imaging. 2018;38(5):788–97.
35.
CraneJDDevriesMCSafdarAHamadehMJTarnopolskyMA. The effect of aging on human skeletal muscle mitochondrial and intramyocellular lipid ultrastructure. J Gerontol A Biol Sci Med Sci. 2010;65(2):119–28.
36.
MiljkovicIKuipersALCauleyJA. Osteoporotic Fractures in Men Study Group. Greater skeletal muscle fat infiltration is associated with higher all-cause and cardiovascular mortality in older men. J Gerontol A Biol Sci Med Sci. 2015;70(9):1133–40.
37.
AthyrosVGAlexandridesTKBilianouH. The use of statins alone, or in combination with pioglitazone and other drugs, for the treatment of non-alcoholic fatty liver disease/non-alcoholic steatohepatitis and related cardiovascular risk. An Expert Panel Statement. Metabolism. 2017;71:17–32.
38.
KatsikiNAthyrosVGMikhailidisDP. Non-alcoholic fatty liver disease in patients with type 2 diabetes mellitus: effects of statins and antidiabetic drugs. J Diabetes Complications. 2017;31(3):521–2.
39.
GreenCJMarjotTTomlinsonJWHodsonL. Of mice and men: is there a future for metformin in the treatment of hepatic steatosis?Diabetes Obes Metab. 2018. doi:10.1111/dom.13592.
40.
RaschiEMazzottiAPoluzziEDe PontiFMarchesiniG. Pharmacotherapy of type 2 diabetes in patients with chronic liver disease: focus on non-alcoholic fatty liver disease. Expert Opin Pharmacother. 2018;19(17):1903–14.
41.
CuiJPhiloLNguyenP. Sitagliptin vs. placebo for non-alcoholic fatty liver disease: a randomized controlled trial. J Hepatol. 2016;65(2):369–76.
42.
KuchayMSKrishanSMishraSK. Effect of empagliflozin on liver fat in patients with type 2 diabetes and nonalcoholic fatty liver disease: a randomized controlled trial (E-LIFT trial). Diabetes Care. 2018;41(8):1801–8.
43.
ErikssonJWLundkvistPJanssonPA. Effects of dapagliflozin and n-3 carboxylic acids on non-alcoholic fatty liver disease in people with type 2 diabetes: a double-blind randomised placebo-controlled study. Diabetologia. 2018;61(9):1923–34.
44.
ArmstrongMJGauntPAithalGP. Liraglutide safety and efficacy in patients with non-alcoholic steatohepatitis (LEAN): a multicentre, double-blind, randomised, placebo-controlled phase 2 study. Lancet. 2016;387(10019):679–90.
45.
KatsikiNMikhailidisDP. Abnormal peri-organ or intra-organ fat deposition and vascular risk. Angiology. 2018;69(10):841–2.
46.
KatsikiNAthyrosVGMikhailidisDP. Abnormal peri-organ or intra-organ fat (APIFat) deposition: an underestimated predictor of vascular risk?Curr Vasc Pharmacol. 2016;14(5):432–41.
47.
GruzdevaOBorodkinaDUchasovaEDylevaYBarbarashO. Localization of fat depots and cardiovascular risk. Lipids Health Dis. 2018;17(1):218.
AldissPDaviesGWoodsRBudgeHSacksHSSymondsME. ‘Browning’ the cardiac and peri-vascular adipose tissues to modulate cardiovascular risk. Int J Cardiol. 2017;228:265–74.
